ArticleNeurobiology of aging2026
Posttraumatic stress disorder is associated with Alzheimer's disease-relevant molecular alterations in the basolateral amygdala of older Veterans.
Article in Neurobiology of aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
Posttraumatic stress disorder (PTSD) is associated with accelerated cognitive aging and increased risk for Alzheimer's disease (AD) and related dementias (ADRD), yet the biological substrates linking trauma-related psychiatric illness to altered brain aging trajectories remain poorly defined. The basolateral amygdala plays a central role in threat processing and emotional memory and exhibits persistent hyperactivity in PTSD, but its molecular and pathological state in aging individuals with PTSD has not been examined. Postmortem basolateral amygdala tissue from older adult donors (≥70 years) with lifetime PTSD (n = 5) and age-matched controls (n = 5) was obtained from the National PTSD Brain Bank. A multimodal analysis integrated immunohistochemical quantification of β-amyloid and phosphorylated tau pathology, targeted transcriptional profiling of AD-related genes, gene network analysis, and protein quantification of pathological, inflammatory, and synaptic markers. PTSD cases showed enrichment of combined tau-amyloid pathology within the basolateral amygdala and greater β-amyloid burden. Targeted transcriptomic profiling identified coordinated upregulation of genes involved in amyloid processing, lipid metabolism, proteostasis, and inflammatory signaling. Network analysis revealed an APP-centered molecular architecture with APOE, and MAPT as hubs. Protein analyses demonstrated increased amyloid-β and pTau231 abundance, markers of gliosis, and synaptic alterations characterized by elevated excitatory receptor expression and reduced inhibitory signaling. Collectively, these findings provide convergent human evidence that PTSD is associated with region-specific molecular alterations engaging pathways implicated in brain aging and neurodegenerative vulnerability. These data suggest that chronic trauma-related circuit dysregulation may intersect with aging-associated inflammatory and synaptic processes, promoting vulnerability to neurodegenerative change within emotionally salient brain circuits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.